A clinical trial was stopped early after researchers found that the bone marrow cancer drug pomalidomide is safe and effective for treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder. Patients taking the drug experienced fewer nosebleeds, required fewer blood transfusions, and reported a better quality of life. This is significant, as there were no reliable treatments.
Bone marrow cancer drug may help treat rare bleeding condition
Hope for long-term relief in HHT.
How the brain transforms sensation into action
Brain-wide decision-making dynamics discovered
This robotic exoskeleton enhances walking efficiency for older
The weight of the WalkON system is just 2.93 KG
Southeast Asia was the main diversification center for the Bananas
If we lose wild banana species, we lose banana's sustainability
Photon momentum effectively turns indirect silicon into direct semiconductor
Optical properties of materials can be dramatically enhanced.
Antarctic Krill locks similar levels of carbon as mangroves
Unveiling the Carbon Storage Potential of Antarctic Krill
New catalyst produces methane using electricity
Methane that doesn’t contribute to global warming.
Cognitive changes linked to COVID-19 identified in study
Study highlights specific changes associated with COVID-19 in particular brain function
Researchers observed the formation of small water bubbles in real time
Scientists witnessed the merging of hydrogen and oxygen atoms.
